Other Updated 2022-10-31

Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy

Recalled Product

CIBINQO (abrocitinib), INREBIC (fedratinib), JAKAVI (ruxolitinib), OLUMIANT (baricitinib), RINVOQ (upadacitinib), XELJANZ/XELJANZ XR (tofacitinib)


Hazard / Issue

New safety information - Product safety

Issued by

Marketed health products

View official government recall

Looking for safe alternatives?

Browse certified-safe products in this category on Amazon Canada →